Valproic Acid Ternary Complexes for Reduced Hepatotoxicity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Valproic acid, despite its effectiveness as an antiepileptic and therapeutic agent, is associated with significant side effects such as hepatotoxicity, teratogenicity, and rare but severe adverse effects, necessitating the development of alternative formulations or derivatives to mitigate these issues.

Innovation Solution

The synthesis of metal-based ternary complexes of valproic acid with nitrogen donor ligands, specifically with diimines or diamines, where the metal is selected from Mg(II) and Zn(II), to create compounds with enhanced pharmacological properties and reduced side effects, such as bis(diisopropylsalicylato)(2,9-dimethylphenanthroline)copper(II), which exhibits cytotoxicity comparable to cisplatin.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If valproic acid is used as an antiepileptic and therapeutic agent, then therapeutic effectiveness is improved, but hepatotoxicity and teratogenicity occur

Engineering Contradiction:
Improvetherapeutic effectivenessVSAvoidhepatotoxicity and teratogenicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent creates ternary metal complexes combining valproic acid with nitrogen donor ligands (diimines or diamines) and metal ions (Mg(II) or Zn(II)). This composite formulation maintains the therapeutic anticonvulsant activity of valproic acid while the metal complex structure reduces the hepatotoxicity and teratogenicity associated with pure valproic acid administration.

Inventive Principle:
Principle #40Composite materials

2Object-affected harmful factors

If metal-based ternary complexes are synthesized, then side effects are reduced, but manufacturing complexity increases

Engineering Contradiction:
Improveside effectsVSAvoidmanufacturing complexity
Core Design Contradiction:
Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The patent systematically varies parameters including metal ion selection (Mg(II), Zn(II)), nitrogen donor ligand types (diimines, diamines), and ligand structures to optimize the balance between reduced side effects and manufacturability. The defined coordination chemistry principles provide a systematic approach to synthesis that manages complexity.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If ternary metal complexes are formed, then therapeutic safety is improved, but drug structure complexity increases

Engineering Contradiction:
Improvetherapeutic safetyVSAvoiddrug structure
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces local structural features through specific nitrogen donor ligands (diimines or diamines) coordinated to metal ions, creating localized functional regions within the complex that enhance safety while maintaining overall structural manageability. The coordination geometry and ligand field properties provide controlled local complexity.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These metal-based ternary complexes demonstrate potent anticonvulsant and anti-inflammatory activities with reduced toxicity, offering a safer treatment option for conditions responsive to valproic acid therapy, including seizures, epilepsy, and inflammatory diseases, while potentially overcoming the adverse effects of valproic acid.

Implementation Method 1

syntheses and antiarthritic activity of copper complexes of non-steroidal anti-inflammatory compounds... These complexes have been found to be more active and desirable drugs that their parent ligands themselves

Methodology Applied
Scientific EffectComplexation: Chemical Bonding

Data Source

PatentEP2440197B1Therapeutical use of ternary complexes of valproic acid
Publication Date: 2019.08.14 UNIVERSITE PARIS SUD 11
  • EP2440197B1 patent drawingFigure 1A~1B
  • EP2440197B1 patent drawingFigure 2
  • EP2440197B1 patent drawingFigure 3

AI summary

A method of treating a human subject having a condition responsive to valproic acid therapy, comprising administering to said subject an effective amount of a metal-based ternary complex of valproic acid with nitrogen donor ligands, in particular with diimines or diamines.